Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Apthorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D'Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, Patriarca A, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D'Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. Cortellini A, et al. Among authors: santoro a. Lancet Oncol. 2023 Apr;24(4):335-346. doi: 10.1016/S1470-2045(23)00056-6. Epub 2023 Mar 7. Lancet Oncol. 2023. PMID: 36898391 Free PMC article.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Garassino MC, et al. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12. Lancet Oncol. 2018. PMID: 29545095 Free PMC article. Clinical Trial.
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS, Laffi A, Gennaro N, Fazio R, D'Orazio F, Samà L, Siracusano LV, Sicoli F, Renne SL, Santoro A, Bertuzzi AF. Grimaudo MS, et al. Among authors: santoro a. Front Oncol. 2023 May 31;13:1190123. doi: 10.3389/fonc.2023.1190123. eCollection 2023. Front Oncol. 2023. PMID: 37324004 Free PMC article.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: santoro a. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.
Losurdo A, Dipasquale A, Giordano L, Persico P, Lorenzi E, Di Muzio A, Barigazzi C, Korolewicz J, Mehan A, Mohammed O, Scheiner B, Pinato DJ, Santoro A, Simonelli M. Losurdo A, et al. Among authors: santoro a. Front Immunol. 2024 Jan 15;15:1323151. doi: 10.3389/fimmu.2024.1323151. eCollection 2024. Front Immunol. 2024. PMID: 38298193 Free PMC article.
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: santoro a. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
Clinical Review on the Management of Breast Cancer Visceral Crisis.
Benvenuti C, Gaudio M, Jacobs F, Saltalamacchia G, De Sanctis R, Torrisi R, Santoro A, Zambelli A. Benvenuti C, et al. Among authors: santoro a. Biomedicines. 2023 Apr 3;11(4):1083. doi: 10.3390/biomedicines11041083. Biomedicines. 2023. PMID: 37189701 Free PMC article. Review.
Opportunities and Challenges of Synthetic Data Generation in Oncology.
Jacobs F, D'Amico S, Benvenuti C, Gaudio M, Saltalamacchia G, Miggiano C, De Sanctis R, Della Porta MG, Santoro A, Zambelli A. Jacobs F, et al. Among authors: santoro a. JCO Clin Cancer Inform. 2023 Aug;7:e2300045. doi: 10.1200/CCI.23.00045. JCO Clin Cancer Inform. 2023. PMID: 37535875 Free article. Review.
3,008 results